Why it matters now
Demand for plasma-derived therapies is experiencing sustained growth, driven by advancements in medical treatments and an expanding patient population with chronic conditions. These therapies are critical for a range of serious illnesses, making a consistent and adequate supply of plasma essential. However, the collection process is complex and resource-intensive, leading to ongoing concerns about capacity. Businesses in this sector must understand the dynamics of supply and demand to ensure patient access, manage production pipelines, and secure their long-term operational viability.
Who is exposed
Plasma product manufacturers face direct exposure to supply chain disruptions and potential production shortfalls if collection capacity lags. Blood banks are impacted by the need to scale collection efforts and manage donor recruitment. Healthcare providers using plasma therapies could experience challenges in patient access and treatment delays. This affects manufacturing output, inventory levels, and ultimately, the ability to deliver life-saving treatments, underscoring the critical nature of maintaining a robust supply.
Most relevant for: Supply Chain Manager, Operations Director, Investment Analyst
What this Viewpoint covers
- What are the current global trends in plasma collection volume?
- How is demand for key plasma-derived therapies projected to evolve?
- Which factors limit the expansion of plasma collection capacity?
- What are the regional variations in collection infrastructure and donor availability?
- How do regulatory changes impact plasma collection and supply chain stability?
Signals to watch
- Announcements of new plasma collection center openings or closures.
- Changes in donor eligibility criteria or compensation policies.
- Reports on global plasma inventory levels.
- Clinical trial data indicating new uses or expanded patient populations for plasma therapies.
Decisions it supports
- Evaluate investment in new plasma collection centers or technology.
- Adjust manufacturing forecasts based on projected plasma availability.
- Develop strategies for diversifying plasma sourcing or enhancing donor recruitment.
How it is built
Prepared after your order from dated public sources - such as medical devices & healthcare filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
Why is plasma collection capacity a concern?
Plasma collection is a highly regulated and labor-intensive process that relies on voluntary donations. Expanding capacity requires significant investment in infrastructure, trained personnel, and robust donor recruitment programs. The increasing demand for therapies, combined with these inherent complexities, creates ongoing challenges in ensuring a sufficient and stable supply, making capacity a critical bottleneck.
What types of therapies rely on plasma?
Plasma is essential for producing a wide range of life-saving therapies, including immunoglobulins for immune deficiencies, albumin for critical care, clotting factors for bleeding disorders, and alpha-1 antitrypsin for genetic lung conditions. These therapies are often vital for managing chronic diseases and acute medical emergencies, highlighting the broad impact of plasma supply on patient health.
How can companies increase plasma supply?
Companies can increase supply by expanding their network of collection centers, investing in advanced plasmapheresis technology to improve efficiency, and implementing innovative donor recruitment and retention programs. Collaborating with blood banks and advocating for supportive regulatory environments can also contribute to a more robust and responsive plasma supply chain, addressing the growing demand.